公开(公告)号：US20220105027A1

公开(公告)日：2022-04-07

申请号：US17273392

申请日：2019-09-06

申请人： Teva Pharmaceutical Industries Ltd.

发明人： Prakash SUNDARAMURTHI ,  Ivana MIJAKOVAC ,  Andrea RASIC ,  Iva TUNJIC

IPC分类号： A61K9/00 ,  A61K31/566 ,  A61K47/10 ,  A61K31/255 ,  A61K47/20 ,  A61K47/02

摘要： The disclosure is directed to medroxyprogesterone compositions suitable for subcutaneous injection comprising about 260 mg/ml to 440 mg/ml medroxyprogesterone acetate, about 0.6 mg/ml to 1.5 mg/ml docusate sodium and, polyethylene glycol. Methods of using these compositions are also described.

公开(公告)号：US20210315905A9

公开(公告)日：2021-10-14

申请号：US16932382

申请日：2020-07-17

申请人： Shimoda Biotech (PTY) Ltd

发明人： Henk SWART

IPC分类号： A61K31/565 ,  A61K47/54 ,  A61K9/00 ,  A61K9/20 ,  A61K31/566 ,  C08B37/16 ,  A61K47/69 ,  A61K9/08 ,  A61K47/40

摘要： Provided are inclusion complexes comprising fulvestrant and a cyclodextrin. The complexes may be useful for treating various conditions, such as cancer and systemic lupus erythematosus. Also provided are methods of producing the inclusion complexes, methods of using the inclusion complexes in therapy, and kits and unit dosages comprising the complexes.

公开(公告)号：US20210228502A1

公开(公告)日：2021-07-29

申请号：US17227320

申请日：2021-04-11

申请人： Richard Postrel

发明人： Richard Postrel

IPC分类号： A61K31/05 ,  A61K31/566 ,  A61K31/192 ,  A61K31/085 ,  A61K31/352 ,  A23K20/184 ,  A23K20/121 ,  A23K20/111

摘要： The present invention discloses a system and method for preparing and delivering various precursor compositions as a replacement therapy for testosterone and other hormone deficiencies that naturally occur with aging in canines and other domesticated animals. Precursor compositions are selected and designed for the purpose of formulating non-toxic therapeutic hormone supplement for oral consumption. The invention features low dose continuous supplementation to be incorporated with daily meals. The process of the present invention delivers an orally ingested substance, e.g., a food, supplement, treat, etc., that contains an anti-aging formulation comprising a hormone precursor (prohormone) that is absorbed by the digestive system and secreted into the bloodstream with a second substance to facitate its ingestion, absorption and delivery to the body's tissues.

公开(公告)号：US20210128463A1

公开(公告)日：2021-05-06

申请号：US17085424

申请日：2020-10-30

申请人： Microchips Biotech, Inc.

发明人： Robert Farra ,  Elizabeth Proos ,  Scott W. James ,  Nicolas J. Pacelli ,  Hong-Ren Wang

IPC分类号： A61K9/00 ,  A61M31/00 ,  A61K47/36 ,  A61K9/20 ,  A61K31/566

摘要： Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

公开(公告)号：US20210059981A1

公开(公告)日：2021-03-04

申请号：US17095876

申请日：2020-11-12

申请人： Michael E. Shanahan ,  Wendy Anne Epstein

发明人： Michael E. Shanahan ,  Wendy Anne Epstein

IPC分类号： A61K31/353 ,  A61K31/566 ,  A61K31/085 ,  A61K9/00

摘要： The invention provides safe and efficacious treatments for Female Sexual Disorders, genitopelvic pain/penetration disorders; vulvovaginal atrophy, vestibulodynia, dyspareunia, sexual interest/arousal disorder, low female libido, and female orgasmic disorder.

公开(公告)号：US20200376005A1

公开(公告)日：2020-12-03

申请号：US16724093

申请日：2019-12-20

申请人： THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK ,  SYRACUSE UNIVERSITY

发明人： WILLIAM G. KERR ,  SONIA IYER ,  JOHN D. CHISHOLM

IPC分类号： A61K31/575 ,  A61K31/566 ,  A61K31/565 ,  A61K31/713 ,  A61K31/4045 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/568 ,  A61K31/5685 ,  A61K31/655 ,  C12N15/113

摘要： The present invention relates to the use of SHIP1 inhibitors and pan-SHIP1/2 inhibitors in various methods, including, without limitation: (i) a method to treat obesity or reduce body fat of an obese subject; (ii) a method to limit bone development in a subject suffering from an osteopetrotic or sclerotic disease; (iii) a method to treat or prevent diabetes; (iv) a method to reduce glucose intolerance or insulin resistance; and (v) a method to lower cholesterol.

公开(公告)号：US20200316091A1

公开(公告)日：2020-10-08

申请号：US16839353

申请日：2020-04-03

申请人： LABORATOIRE HRA-PHARMA

发明人： Camille BANH ,  Pascale BORENSZTEIN ,  Annabelle GLASIER ,  Delphine LEVY-GOMPEL ,  Catherine MONTEIL

IPC分类号： A61K31/57 ,  A61K31/566 ,  A61K9/00 ,  A61K9/70 ,  A61P15/18

摘要： The invention relates to a method for providing contraception in a woman, wherein the woman is subjected to hormonal combined contraceptive but experiments at least one misuse of said hormonal combined contraceptive and wherein the method comprises administering ulipristal acetate or a metabolite thereof within 120 hours after said at least one misuse and resuming the hormonal combined contraceptive within 24 hours after the intake of ulipristal acetate in said woman.

公开(公告)号：US10759826B2

公开(公告)日：2020-09-01

申请号：US16305829

申请日：2017-06-07

申请人： USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. ,  USTAV MOLEKULARNI GENETIKY AKADEMIE VED CR, V.V.I. ,  UNIVERZITA PALACKEHO V OLOMOUCI ,  HELMHOLTZ ZENTRUM MUNCHEN

发明人： Martin Kotora ,  Eva Prchalova ,  Jerzy Adamski ,  Gabriele Moeller ,  Ondrej Stepanek ,  Petr Bartunek ,  David Sedlak ,  Marian Hajduch ,  Petr Dzubak

IPC分类号： A61K31/566 ,  C07J1/00

摘要： 15β-substituted derivatives of estrone of general formula I wherein R1, R2, R3, R4, R5 are independently selected from the group consisting of: C1-C4 alkyl, C1-C4 alkoxy, C1-C4 halogenalkyl, halogen, COOR6 wherein R6 is C1-C4 alkyl; H, OH; optionally, R3, R4 and R5 are each formed by a hydrogen atom, while R1 and R2 together form an aryl group, preferably naphthyl, in which the aromatic ring in position C-15 can be mono-, di-, tri-, tetra- and penta-substituted with substituents R1-R5. Compounds of the invention may be used for diagnosis and possibly also for the treatment of estrogen-dependent diseases.

公开(公告)号：US10653705B2

公开(公告)日：2020-05-19

申请号：US16415543

申请日：2019-05-17

申请人： SHANGHAI JIAO TONG UNIVERSITY

发明人： Yongyong Shi ,  Zhijian Song

IPC分类号： A61K31/566 ,  A61P35/00

摘要： This invention discloses uses for estrone in preparing anti-ovarian cancer and/or breast cancer products. This invention provides uses for estrone in the preparation of products to treat ovarian cancer and/or breast cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug estrone, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that estrone has a new use as an anti-ovarian cancer and/or anti-breast cancer medication, thus achieving a new purpose for an old drug.

公开(公告)号：US10369158B2

公开(公告)日：2019-08-06

申请号：US15307198

申请日：2015-04-27

申请人： The Regents of the University of California

发明人： Rhonda R. Voskuhl

IPC分类号： A61K31/566 ,  A61K31/57 ,  A61K9/00 ,  A61K45/06

摘要： This invention relates to novel packaged pharmaceutical products for the treatment of neurodegenerative diseases, such as multiple sclerosis, and methods of using these products.